Overview

A Study of CTA30X Cell Injection in Patients With Relapsed or Refractory CD19-positive B-line Hematological Malignancies

Status:
Recruiting
Trial end date:
2027-05-31
Target enrollment:
Participant gender:
Summary
A study of CTA30X cell injection in the treatment of relapsed or refractory CD19-positive B-line hematological malignancies
Phase:
Early Phase 1
Details
Lead Sponsor:
He Huang
Collaborator:
Nanjing Bioheng Biotech Co., Ltd.